KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in InventoryDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for BioNTech SE (BNTX) over the last 7 years, with Q3 2025 value amounting to $32.6 million.

  • BioNTech SE's Share-based Compensation fell 2738.49% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.3 million, marking a year-over-year increase of 1771.57%. This contributed to the annual value of $107.8 million for FY2024, which is 9496.35% up from last year.
  • Latest data reveals that BioNTech SE reported Share-based Compensation of $32.6 million as of Q3 2025, which was down 2738.49% from $36.3 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Share-based Compensation registered a high of $73.6 million during Q3 2021, and its lowest value of $20.87 during Q1 2021.
  • In the last 5 years, BioNTech SE's Share-based Compensation had a median value of $22.6 million in 2022 and averaged $26.0 million.
  • Data for BioNTech SE's Share-based Compensation shows a peak YoY increase of 26944123966.81% (in 2021) and a maximum YoY decrease of 9999.98% (in 2021) over the last 5 years.
  • BioNTech SE's Share-based Compensation (Quarter) stood at $23.5 million in 2021, then decreased by 3.42% to $22.6 million in 2022, then plummeted by 32.54% to $15.3 million in 2023, then skyrocketed by 64.36% to $25.1 million in 2024, then increased by 29.88% to $32.6 million in 2025.
  • Its Share-based Compensation stands at $32.6 million for Q3 2025, versus $36.3 million for Q2 2025 and $23.2 million for Q1 2025.